Erythroid progenitor proliferation is stimulated by phenoxyacetic and phenylalkyl acids

Blood Cells, Molecules, and Diseases

Volumn 22, Issue 2, 1996, Pages 150-158

  Torkelson, Steven ^a   White, Brian ^a   Faller, Douglas V ^a   Phipps, Krista ^a   Pantazis, Cooley ^b   Perrine, Susan P ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

erythropoiesis; fetal hemoglobin; hemoglobinopathies; metabolic transport; phenoxyacetic acids; phenylalkyl acids

Indexed keywords

2 DIMETHYL 2 PHENYLACETIC ACID; 2,2 DIMETHYLBUTYRIC ACID; 3 PHENYLBUTYRIC ACID; ALPHA METHYLCINNAMIC ACID; ARGININE BUTYRATE; HEMOGLOBIN F; PHENOXYACETIC ACID; THIOPHENOXYACETIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ERYTHROID CELL; ERYTHROPOIESIS; HEMOGLOBINOPATHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0030221901     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.1996.0022     Document Type: Article

References (27)

1. 1. Distel RJ, Robinson GS, and Spiegelman BM. Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms. J Biol Chem 267:5937-5941, 1992.
2. 2. Ginder G, Whitters MJ, Pohlman JK. Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. Proc Natl Acad Sci USA 81:3954-3957, 1984.
3. 3. Perrine SP, Miller BA, Greene MF, Cohen RA, Cook N, Shackleton C, et al. Butyric acid analogues augment gamma globin gene expression in neo-natal erythroid progenitors. Biochem Biophys Res Commun 148:694-700, 1987.
4. 4. Constantoulakis P, Knitter G, Stamatoyannopoulos G. On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-azaC and araC. Blood 74:1963-1971, 1989.
5. 5. Fibach E, Prasanna P, Rodgers GP, Samid D. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and β-thalassemia. Blood 82:2203-2209, 1993.
6. 6. Safaya S, Ibrahim A, Reider RF. Augmentation of γ-globin gene promoter activity by carboxylic acids and components of the human β-globin locus control region. Blood 84:3929-3935, 1994.
7. 7. Stamatoyannopoulos G, Blau CA, Nakamoto B, et al. Fetal hemoglobin induction by acetate, a product of butyrate catabolism. Blood 84:3198-3204, 1994.
8. 8. Liakopoulou E, Blau CA, Li QL, et al. Stimulation of fetal hemoglobin production by short chain fatty acids. Blood 86:3227-3235, 1995.
9. 9. Perrine SP, Rudolph A, Faller DV, Cohen RA, Chen S-J, Kan YW. Butyrate infusions in the ovine fetus delay the biological clock for globin gene switching. Proc Natl Acad Sci USA 85:8540-8542, 1988.
10. 10. Perrine SP, Miller BA, Faller DV, et al. Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and β-thalassemia. Blood 74:454-460, 1989.
11. 11. Perrine SP, Dover GH, Daftari P, et al. Isobutyramide, an orally bioavailable butyrate analogue, stimulates fetal globin gene expression in vitro and in vivo. Brit J Haemat 88:555-561, 1994.
12. 12. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin gene expression in the β-globin disorders. N Engl J Med 328:81-86, 1993.
13. 13. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84:339-343, 1994.
14. 14. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous β-thalassemia: a clinical trial. Blood 85: 43-49, 1995.
15. 15. Brauer M, Al-Momen AK, Faller DV. Butyrate treatment in beta-hemoglobinopathies [letter; comment]. N Engl J Med 333:1287, 1995.
16. 16. Faller DV, Perrine SP. Butyrate in the treatment of sickle cell disease and β-thalassemia. Curr Opin Hemat 2:109-117, 1995.
17. 17. Daniel P, Brazier M, Cerutti I, et al. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. Clin Chim Acta 181:255-264, 1989.
18. 18. Toscani A, Soprano DR, Soprano KJ. Molecular analysis of sodium butyrate-induced growth arrest. Oncogene Res 3:223-238, 1988.
19. 1 phase. J Cell Biochem 21:239-247, 1983.
20. 1 progression in chemically transformed mouse fibroblasts BP-A31. J Cell Phys 145:46-52, 1990.
21. 21. Darzynkiewicz Z, Traganos F, Xue S, Melamed MR. Effect of n-butyrate on cell cycle progression and in situ chromatin structure of L1210 cells. Exp Cell Res 136:279-293, 1981.
22. 22. Vagdama JV, Castro M, Christensen HN. Characterization of amino acid transport during erythroid cell differentiation. J Biol Chem 262:13273-13284, 1987.
23. 23. Yen A, Pardee AB. Arrested states produced by isoleucine deprivation and their relationship to the low serum produced arrested state in Swiss 3T3 cells. Exp Cell Res 114:389-394, 1978.
24. 24. Yuan J, Angelucci E, Lucarelli G, et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe β-thalassemia (Cooley's Anemia). Blood 82: 374-377, 1993.
25. 25. Ludescher C, Thaler J, Drach D, et al. Detection of activity of P-glycoprotein in human tumor samples using rhodamine 123. Br J Haematol 82: 161-168, 1992.
26. 26. Bates SE, Currier SJ, Alvarez M, Fojo AT. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry 31: 6366-6372, 1992.
27. + human umbilical cord blood hematopoietic progenitors with high proliferative and replating potential. Blood 81:41-48, 1993.